Non High-Density Lipoprotein Cholesterol in Type2 Diabetic Patients
Asian Journal of Research and Reports in Endocrinology,
Aims: To study the relationship between non high-density lipoprotein cholesterol (non-HDL-C) and metabolic disorders in type2 diabetic patients and to prove the incrimination of non-HDL-C in the genesis of chronic complications of diabetes.
Study Design: Retrospective study.
Place and Duration of Study: Endocrinology-Diabetology Department of Hedi Chaker University Hospital of Sfax for a period of two months, January and February 2020.
Methodology: We included80 type2 diabetic patients (34 men and 46 women; age range: 22-72 years) with metabolic syndrome. Each patient had undergone a complete clinical examination and biochemistry test, then, the non-HDL-C was calculated.
Results: Out of 80 patients, 57 suffered from diabetic complications like micro vascular and macro vascular complications. Unbalanced diabetes was identified in 73.75% of the patients. All the patients had a high level of non-HDL-C.
No significant positive correlation was confirmed between non-HDL-C with body mass index, glycemic parameters, triglycerides, or total cholesterol.
Correlation between the level of non-HDL-C and coronary artery disease, myocardial infarction (MI), and stroke was identified with p values of 0.016, 0.05, and 0.04, respectively.
Patients with microvascular complications had higher levels of non-HDL-C but a positive correlation was only relevant with diabetic nephropathy (p=0.026).
Conclusion: Our study confirmed that non-HDL-C is a simple and reliable indicator of the overall risk of cardiovascular disease, thus, it may be equivalent, if not superior, to low-density lipoprotein cholesterol (LDL-C). Therefore, it should be our primary lipid treatment target for diabetic patients.
- Non-high-density lipoprotein cholesterol
- diabetic complications
- metabolic syndrome
How to Cite
Di Angelantonio E, Gao P, Pennells L, Kaptoge S, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499-2506.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486-97.
See Lu et Al. Non–HDL Cholesterol: Into the Spotlight. Editorial. Diabetes Care. 2003 26(1):240-42
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.
Huang J, Parish R, Mansi I, Yu H, Kennen EM, et al. Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. J Investig Med. 2008;56:931-936.
Li C, Ford ES, McBride PE, Kwiterovich PO, McCrindle BW, et al. Non-highdensity lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12-19 years. J Pediatr. 2011;158:201-207.
Poirier P, Després JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil. 2003;23:161–9.
Kengo Moriyama, Eiko Takahashi J. Non-HDL cholesterol is a more superior predictor of small-dense LDL cholesterol than LDL cholesterol in Japanese subjects with TG levels 400 mg/dL. AtherosclerThromb. 2016;23:1126-1137.
Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National lipid association taskforce on non-hdl cholesterol: The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008;2:267-273.
Balkau B, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyöralä K. Does the metabolic syndrome detect further subjects at high risk of cardiovascular risk score adequate Diabetologia. 2005;48:A119.
Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. J Diabetes. 2015;7:523-530.
Reiko Seki, Kazuo Inoue, Sayaka Yamamoto, Kimihiko Akimoto. Non-HDL cholesterol is better than friedewald-estimated LDL cholesterol to associate with cardiometabolic markers. 2017;2(2): 1-6.
Di AngelantonioE, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
Salim S. Virani MD. Non-HDL cholesterol as a metric of good quality of care opportunities and challenges. 2011;38(2): 160-62.
Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retentionas the initiating process in atherosclerosis: Update and therapeutic implications. Circulation. 2007;116:1832–44.
Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2007;27: 661–70.
Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNAGuideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139:1082–143.
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–97.
Keys A, Karvonen MJ, Punsar S, Menotti A, Fidanza F, Farchi G. HDL serum cholesterol and 22-year mortality of men in Finland. Intl J Epidemiol. 1984;13:428–435.
Menotti A, Kromhout D, Nissinen A, Giampaoli S, Seccareccia F, Feskens E, Pekkanen J, Tervahauta M. Short-term all-cause mortality and its determinants in elderly male populations in Finland, the Netherlands, and Italy: The FINE Study. Prev Med. 1996:25:319–326.
Lehto S, Ronnemaa T, HaffnerSM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997:46:1354–1359.
Reed D, Benfante R. Lipid and lipoprotein predictors of coronary heart disease in elderly men in the Honolulu Heart Program. Ann Epidemiol. 1992;2:29–34.
Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, CastelliWP, Wilson PWF. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35:779–792.
Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, BachorikPS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Int Med. 2001;161:1413–1419.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97.
Task Force Members; ESC committee for practice guidelines (CPG); ESC national cardiac societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.
Abstract View: 95 times
PDF Download: 52 times